Real-world outcomes, treatment patterns and T790M testing rates in non-small cell lung cancer patients treated with first-line first- or second-generation epidermal growth factor receptor tyrosine kinase inhibitors from the Slovenian cohort of the REFLECT study

1Planchard D, Popat S, Kerr K, Novello S, Smit EF, Faivre-Finn C, et al. Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up [published correction appears in Ann Oncol 2019; 30: 863-70]. Ann Oncol 2018; 29(Suppl 4): iv192-237. doi: 10.1093/annonc/mdy275 Planchard D Popat S Kerr K Novello S Smit EF Faivre-Finn C et al Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis treatment and follow-up [published correction appears in Ann Oncol 2019 30 863 70 Ann Oncol 2018; 29(Suppl 4): iv192-237 10.1093/annonc/mdy27530285222Open DOISearch in Google Scholar

2World Health Organization. International Agency for Research on Cancer (IARC). GLOBOCAN 2020. Cancer today. Lung. [internet]. [cited 2021 Feb 16]. Available at: https://gco.iarc.fr/today/data/factsheets/cancers/15-Lung-fact-sheet.pdf World Health Organization International Agency for Research on Cancer (IARC). GLOBOCAN 2020. Cancer today. Lung. [internet]. [cited 2021 Feb 16] Available at https://gco.iarc.fr/today/data/factsheets/cancers/15-Lung-fact-sheet.pdfSearch in Google Scholar

3Carcereny E, Morán T, Capdevila L, Cros S, Vilà L, de Los Llanos Gil M, et al. The epidermal growth factor receptor (EGRF) in lung cancer. Transl Respir Med 2015; 3: 1. doi: 10.1186/s40247-015-0013-z Carcereny E Morán T Capdevila L Cros S Vilà L de Los Llanos Gil M et al The epidermal growth factor receptor (EGRF) in lung cancer Transl Respir Med 2015 3 1 10.1186/s40247-015-0013-z436643225810955Open DOISearch in Google Scholar

4Gelatti ACZ, Drilon A, Santini FC. Optimizing the sequencing of tyrosine kinase inhibitors (TKIs) in epidermal growth factor receptor (EGFR) mutation-positive non-small cell lung cancer (NSCLC). Lung Cancer 2019; 137: 113-22. doi: 10.1016/j.lungcan.2019.09.017 Gelatti ACZ Drilon A Santini FC Optimizing the sequencing of tyrosine kinase inhibitors (TKIs) in epidermal growth factor receptor (EGFR) mutation-positive non-small cell lung cancer (NSCLC) Lung Cancer 2019 137 113 22 10.1016/j.lungcan.2019.09.017747884931568888Open DOISearch in Google Scholar

5Vansteenkiste J, Wauters E. Tyrosine kinase inhibition of EGFR: a successful history of targeted therapy for NSCLC since 20 years. Ann Oncol 2018; 29(Suppl 1): i1-i2. doi: 10.1093/annonc/mdx724 Vansteenkiste J Wauters E Tyrosine kinase inhibition of EGFR: a successful history of targeted therapy for NSCLC since 20 years Ann Oncol 2018 29Suppl 1 i1 i2 10.1093/annonc/mdx72429462258Open DOISearch in Google Scholar

6Westover D, Zugazagoitia J, Cho BC, Lovly CM, Paz-Ares L. Mechanisms of acquired resistance to first- and second-generation EGFR tyrosine kinase inhibitors. Ann Oncol 2018; 29(Suppl 1): i10-i19. doi: 10.1093/annonc/mdx703 Westover D Zugazagoitia J Cho BC Lovly CM Paz-Ares L Mechanisms of acquired resistance to first- and second-generation EGFR tyrosine kinase inhibitors Ann Oncol 2018 29Suppl 1 i10 i19 10.1093/annonc/mdx703645454729462254Open DOISearch in Google Scholar

7Santoni-Rugiu E, Melchior LC, Urbanska EM, Jakobsen JN, Stricker K, Grauslund M, et al. Intrinsic resistance to EGFR-tyrosine kinase inhibitors in EGFR-mutant non-small cell lung cancer: differences and similarities with acquired resistance. Cancers 2019; 11: 923. doi: 10.3390/cancers11070923 Santoni-Rugiu E Melchior LC Urbanska EM Jakobsen JN Stricker K Grauslund M et al Intrinsic resistance to EGFR-tyrosine kinase inhibitors in EGFR-mutant non-small cell lung cancer: differences and similarities with acquired resistance Cancers 2019 11 923 10.3390/cancers11070923667866931266248Open DOISearch in Google Scholar

8Mok TS, Wu Y-L, Ahn M-J, Kim HR, Ramalingam SS, Shepherd FA, et al. Osimertinib or platinum-pemetrexed in EGFR T790M-positive lung cancer. N Engl J Med 2017; 376: 629-40. doi: 10.1056/NEJMoa1612674 Mok TS Wu Y-L Ahn M-J Kim HR Ramalingam SS Shepherd FA et al Osimertinib or platinum-pemetrexed in EGFR T790M-positive lung cancer N Engl J Med 2017 376 629 40 10.1056/NEJMoa1612674676202727959700Open DOISearch in Google Scholar

9Soria JC, Ohe Y, Vansteenkiste J, Reungwetwattana T, Chewaskulyong B, Lee KH, et al. Osimertinib in untreated EGFR-mutated advanced non-small-cell lung cancer. N Engl J Med 2018; 378: 113-25. doi: 10.1056/NEJMoa1713137 Soria JC Ohe Y Vansteenkiste J Reungwetwattana T Chewaskulyong B Lee KH et al Osimertinib in untreated EGFR-mutated advanced non-small-cell lung cancer N Engl J Med 2018 378 113 25 10.1056/NEJMoa171313729151359Open DOISearch in Google Scholar

10Cufer T, Ciuleanu TE, Berzinec P, Galffy G, Jakopovic M, Jassem J, et al. Access to novel drugs for non-small cell lung cancer in Central and Southeastern Europe: a Central European Cooperative Oncology Group analysis. Oncologist 2020; 25: e598-601. doi: 10.1634/theoncologist.2019-0523 Cufer T Ciuleanu TE Berzinec P Galffy G Jakopovic M Jassem J et al Access to novel drugs for non-small cell lung cancer in Central and Southeastern Europe: a Central European Cooperative Oncology Group analysis Oncologist 2020 25 e598 601 10.1634/theoncologist.2019-0523706671732162818Open DOISearch in Google Scholar

11Ryska A, Berzinec P, Brcic L, Cufer T, Dziadziuszko R, Gottfried M, et al. NSCLC molecular testing in Central and Eastern European countries. BMC Cancer 2018; 18: 269. doi: 10.1186/s12885-018-4023-4 Ryska A Berzinec P Brcic L Cufer T Dziadziuszko R Gottfried M et al NSCLC molecular testing in Central and Eastern European countries BMC Cancer 2018 18 269 10.1186/s12885-018-4023-4584518429523116Open DOISearch in Google Scholar

12Zadnik V, Primic Zakelj M, Lokar K, Jarm K, Ivanus U, Zagar T. Cancer burden in Slovenia with the time trends analysis. Radiol Oncol 2017; 51: 47-55. doi: 10.1515/raon-2017-0008 Zadnik V Primic Zakelj M Lokar K Jarm K Ivanus U Zagar T Cancer burden in Slovenia with the time trends analysis Radiol Oncol 2017 51 47 55 10.1515/raon-2017-0008533017428265232Open DOISearch in Google Scholar

13Zwitter M, Čufer T, Vrankar M, Kern I, Štupnik T, Rozman A, et al. Lung cancer in Slovenia. J Thorac Oncol 2019; 14: 1327-31. doi: 10.1016/j. jtho.2019.02.025 Zwitter M Čufer T Vrankar M Kern I Štupnik T Rozman A et al Lung cancer in Slovenia J Thorac Oncol 2019 14 1327 31 10.1016/j.jtho.2019.02.02531345331Open DOISearch in Google Scholar

14Zanetti R, Sacchetto L, Coebergh JW, Rosso S. To accelerate cancer prevention in Europe: challenges for cancer registries. Eur J Cancer 2018; 104: 151-9. doi: 10.1016/j.ejca.2018.09.001 Zanetti R Sacchetto L Coebergh JW Rosso S To accelerate cancer prevention in Europe: challenges for cancer registries Eur J Cancer 2018 104 151 9 10.1016/j.ejca.2018.09.00130352383Open DOISearch in Google Scholar

15Thunissen E, Weynand B, Udovicic-Gagula D, Brcic L, Szolkowska M, Hofman P, et al. Lung cancer biomarker testing: perspective from Europe. Transl Lung Cancer Res 2020; 9: 887-897. doi: 10.21037/tlcr.2020.04.07 Thunissen E Weynand B Udovicic-Gagula D Brcic L Szolkowska M Hofman P et al Lung cancer biomarker testing: perspective from Europe Transl Lung Cancer Res 2020 9 887 897 10.21037/tlcr.2020.04.07735411932676354Open DOISearch in Google Scholar

16Janzic U, Knez L, Janzic A, Cufer T. Time to access to novel anticancer drugs and the correlation with ESMO-magnitude of clinical benefit scale in Slovenia. Expert Rev Pharmacoecon Outcomes Res 2019; 19: 717-23. doi: 10.1080/14737167.2019.1702879 Janzic U Knez L Janzic A Cufer T Time to access to novel anticancer drugs and the correlation with ESMO-magnitude of clinical benefit scale in Slovenia Expert Rev Pharmacoecon Outcomes Res 2019 19 717 23 10.1080/14737167.2019.170287931826655Open DOISearch in Google Scholar

17Hirsh V, Singh J. Optimal sequencing strategies in the treatment of EGFR mutation-positive non-small cell lung cancer: clinical benefits and cost-effectiveness. Am J Health Syst Pharm 2020; 77: 1466-76. doi: 10.1093/ ajhp/zxaa197 Hirsh V Singh J Optimal sequencing strategies in the treatment of EGFR mutation-positive non-small cell lung cancer: clinical benefits and cost-effectiveness Am J Health Syst Pharm 2020 77 1466 76 10.1093/ajhp/zxaa197747221032885829Open DOISearch in Google Scholar

18Leduc C, Merlio JP, Besse B, Blons H, Debieuvre D, Bringuier PP, et al. Clinical and molecular characteristics of non-small-cell lung cancer (NSCLC) harboring EGFR mutation: results of the nationwide French Cooperative Thoracic Intergroup (IFCT) program. Ann Oncol 2017; 28: 2715-24. doi: 10.1093/ annonc/mdx404 Leduc C Merlio JP Besse B Blons H Debieuvre D Bringuier PP et al Clinical and molecular characteristics of non-small-cell lung cancer (NSCLC) harboring EGFR mutation: results of the nationwide French Cooperative Thoracic Intergroup (IFCT) program Ann Oncol 2017 28 2715 24 10.1093/annonc/mdx40428945865Open DOISearch in Google Scholar

19Syrigos KN, Georgoulias V, Zarogoulidis K, Makrantonakis P, Charpidou A, Christodoulou C. Epidemiological characteristics, EGFR status and management patterns of advanced non-small cell lung cancer patients: the Greek REASON observational registry study. Anticancer Res 2018; 38: 3735-44. doi: 10.21873/anticanres.12654 Syrigos KN Georgoulias V Zarogoulidis K Makrantonakis P Charpidou A Christodoulou C Epidemiological characteristics, EGFR status and management patterns of advanced non-small cell lung cancer patients: the Greek REASON observational registry study Anticancer Res 2018 38 3735 44 10.21873/anticanres.1265429848736Open DOISearch in Google Scholar

20Schuette W, Schirmacher P, Eberhardt WEE, Dietel M, Zirrgiebel U, Muehlenhoff L, et al. Treatment decisions, clinical outcomes, and pharmacoeconomics in the treatment of patients with EGFR mutated stage III/IV NSCLC in Germany: an observational study. BMC Cancer 2018; 18: 135. doi: 10.1186/s12885-018-4032-3 Schuette W Schirmacher P Eberhardt WEE Dietel M Zirrgiebel U Muehlenhoff L et al Treatment decisions, clinical outcomes, and pharmacoeconomics in the treatment of patients with EGFR mutated stage III/IV NSCLC in Germany: an observational study BMC Cancer 2018 18 135 10.1186/s12885-018-4032-3579990429402243Open DOISearch in Google Scholar

21Reale ML, Chiari R, Tiseo M, Vitiello F, Barbieri F, Cortinovis D, et al. Be-TeaM: an Italian real-world observational study on second-line therapy for EGFR-mutated NSCLC patients. Lung Cancer 2020; 140: 71-9. doi: 10.1016/j. lungcan.2019.12.006 Reale ML Chiari R Tiseo M Vitiello F Barbieri F Cortinovis D et al Be-TeaM: an Italian real-world observational study on second-line therapy for EGFR-mutated NSCLC patients Lung Cancer 2020 140 71 9 10.1016/j.lungcan.2019.12.00631884129Open DOISearch in Google Scholar

22Pluzanski A, Krzakowski M, Kowalski D, Dziadziuszko R. Real-world clinical outcomes of first-generation and second-generation epidermal growth factor receptor tyrosine kinase inhibitors in a large cohort of European non-small-cell lung cancer patients. ESMO Open 2020; 5: e001011. doi: 10.1136/ esmoopen-2020-001011 Pluzanski A Krzakowski M Kowalski D Dziadziuszko R Real-world clinical outcomes of first-generation and second-generation epidermal growth factor receptor tyrosine kinase inhibitors in a large cohort of European non-small-cell lung cancer patients ESMO Open 2020 5 e001011 10.1136/esmoopen-2020-001011764061933148621Open DOISearch in Google Scholar

23Pereira I, Gaspar C, Pina M, Azevedo I, Rodrigues A. Real-world T790M mutation frequency and impact of rebiopsy in patients with EGFR-mutated advanced non-small cell lung cancer. Cureus 2020; 12: e12128. doi: 10.7759/ cureus.12128 Pereira I Gaspar C Pina M Azevedo I Rodrigues A Real-world T790M mutation frequency and impact of rebiopsy in patients with EGFR-mutated advanced non-small cell lung cancer Cureus 2020 12 e12128 10.7759/cureus.12128781017533489541Open DOISearch in Google Scholar

24Gijtenbeek RGP, Damhuis RAM, Groen HJM, van der Wekken AJ, van Geffen WH. Nationwide real-world cohort study of first-line tyrosine kinase inhibitor treatment in epidermal growth factor receptor-mutated non-small-cell lung cancer. Clin Lung Cancer 2020; 21: e647-53. doi: 10.1016/j. cllc.2020.05.019 Gijtenbeek RGP Damhuis RAM Groen HJM van der Wekken AJ van Geffen WH Nationwide real-world cohort study of first-line tyrosine kinase inhibitor treatment in epidermal growth factor receptor-mutated non-small-cell lung cancer Clin Lung Cancer 2020 21 e647 53 10.1016/j.cllc.2020.05.01932636159Open DOISearch in Google Scholar

25Chiang AC, Fernandes AW, Pavilack M, Wu JW, Laliberté F, Duh MS, et al. EGFR mutation testing and treatment decisions in patients progressing on first- or second-generation epidermal growth factor receptor tyrosine kinase inhibitors. BMC Cancer 2020; 20: 356. doi: 10.1186/s12885-020-06826-0 Chiang AC Fernandes AW Pavilack M Wu JW Laliberté F Duh MS et al EGFR mutation testing and treatment decisions in patients progressing on first- or second-generation epidermal growth factor receptor tyrosine kinase inhibitors BMC Cancer 2020 20 356 10.1186/s12885-020-06826-0718968832345265Open DOISearch in Google Scholar

26Cuppens K, Lodewyckx L, Demedts I, Decoster L, Colinet B, Deschepper K, et al. Real-world treatment patterns, epidermal growth factor receptor (EGFR) testing and outcomes in EGFR-mutated advanced non-small cell lung cancer patients in Belgium: results from the REVEAL study. Drugs Real World Outcomes 2021; 8: 141-52. doi: 10.1007/s40801-021-00243-w Cuppens K Lodewyckx L Demedts I Decoster L Colinet B Deschepper K et al Real-world treatment patterns, epidermal growth factor receptor (EGFR) testing and outcomes in EGFR-mutated advanced non-small cell lung cancer patients in Belgium: results from the REVEAL study Drugs Real World Outcomes 2021 8 141 52 10.1007/s40801-021-00243-w812895333710523Open DOISearch in Google Scholar

27Addeo A, Hochmair M, Janzic U, Dudnik E, Charpidou A, Płużański A, et al. Treatment patterns, testing practices, and outcomes in the pre-FLAURA era for patients with EGFR mutation-positive advanced NSCLC: a retrospective chart review (REFLECT). Ther Adv Med Oncol 2021; 13: 1-11. doi: 10.1177/17588359211059874 Addeo A Hochmair M Janzic U Dudnik E Charpidou A Płużański A et al Treatment patterns, testing practices, and outcomes in the pre-FLAURA era for patients with EGFR mutation-positive advanced NSCLC: a retrospective chart review (REFLECT) Ther Adv Med Oncol 2021 13 1 11 10.1177/17588359211059874884214935173817Open DOISearch in Google Scholar

28Goto Y, Tanai C, Yoh K, Hosomi Y, Sakai H, Kato T, et al. Continuing EGFR-TKI beyond radiological progression in patients with advanced or recurrent, EGFR mutation-positive non-small-cell lung cancer: an observational study. ESMO Open 2017; 2: e000214. doi: 10.1136/esmoopen-2017-000214 Goto Y Tanai C Yoh K Hosomi Y Sakai H Kato T et al Continuing EGFR-TKI beyond radiological progression in patients with advanced or recurrent, EGFR mutation-positive non-small-cell lung cancer: an observational study ESMO Open 2017 2 e000214 10.1136/esmoopen-2017-000214560471529018574Open DOISearch in Google Scholar

29Unk M, Mohorčič K, Osrajnik I, Čufer T. Lung cancer – Slovenian clinical practice guidelines in systemic treatment 2017. [Slovenian]. Onkologija 2017; 21: 52-62. Unk M Mohorčič K Osrajnik I Čufer T Lung cancer – Slovenian clinical practice guidelines in systemic treatment 2017 [Slovenian]. Onkologija 2017 21 52 62Search in Google Scholar

30Minari R, Mazzaschi G, Bordi P, Gnetti L, Alberti G, Altimari A, et al. Detection of EGFR-activating and T790M mutations using liquid biopsy in patients with EGFR-mutated non-small-cell lung cancer whose disease has progressed during treatment with first- and second-generation tyrosine kinase inhibitors: a multicenter real-life retrospective study. Clin Lung Cancer 2020; 21: e464-73. doi: 10.1016/j.cllc.2020.02.021 Minari R Mazzaschi G Bordi P Gnetti L Alberti G Altimari A et al Detection of EGFR-activating and T790M mutations using liquid biopsy in patients with EGFR-mutated non-small-cell lung cancer whose disease has progressed during treatment with first- and second-generation tyrosine kinase inhibitors: a multicenter real-life retrospective study Clin Lung Cancer 2020 21 e464 73 10.1016/j.cllc.2020.02.02132276870Open DOISearch in Google Scholar

31Dal Maso A, Lorenzi M, Roca E, Pilotto S, Macerelli M, Polo V, et al. Clinical features and progression pattern of acquired T790M-positive compared with T790M-negative EGFR mutant non-small-cell lung cancer: catching tumor and clinical heterogeneity over time through liquid biopsy. Clin Lung Cancer 2020; 21: 1-14.e3. doi: 10.1016/j.cllc.2019.07.009 Dal Maso A Lorenzi M Roca E Pilotto S Macerelli M Polo V et al Clinical features and progression pattern of acquired T790M-positive compared with T790M-negative EGFR mutant non-small-cell lung cancer: catching tumor and clinical heterogeneity over time through liquid biopsy Clin Lung Cancer 2020 21 1 14 e3 10.1016/j.cllc.2019.07.00931601525Open DOISearch in Google Scholar

32Owen S, Souhami L. The management of brain metastases in non-small cell lung cancer. Front Oncol 2014; 4: 248. doi: 10.3389/fonc.2014.00248 Owen S Souhami L The management of brain metastases in non-small cell lung cancer Front Oncol 2014 4 248 10.3389/fonc.2014.00248416409625309873Open DOISearch in Google Scholar

33Page S, Milner-Watts C, Perna M, Janzic U, Vidal N, Kaudeer N, et al. Systemic treatment of brain metastases in non-small cell lung cancer. Eur J Cancer 2020; 132: 187-98. doi: 10.1016/j.ejca.2020.03.006 Page S Milner-Watts C Perna M Janzic U Vidal N Kaudeer N et al Systemic treatment of brain metastases in non-small cell lung cancer Eur J Cancer 2020 132 187 98 10.1016/j.ejca.2020.03.00632380429Open DOISearch in Google Scholar

34Li L, Luo S, Lin H, Yang H, Chen H, Liao Z, et al. Correlation between EGFR mutation status and the incidence of brain metastases in patients with non-small cell lung cancer. J Thorac Dis 2017; 9: 2510-20. doi: 10.21037/ jtd.2017.07.57 Li L Luo S Lin H Yang H Chen H Liao Z et al Correlation between EGFR mutation status and the incidence of brain metastases in patients with non-small cell lung cancer J Thorac Dis 2017 9 2510 20 10.21037/jtd.2017.07.57559420128932557Open DOISearch in Google Scholar

35Stanic K, Zwitter M, Hitij NT, Kern I, Sadikov A, Cufer T. Brain metastases in lung adenocarcinoma: impact of EGFR mutation status on incidence and survival. Radiol Oncol 2014; 48: 173-83. doi: 10.2478/raon-2014-0016 Stanic K Zwitter M Hitij NT Kern I Sadikov A Cufer T Brain metastases in lung adenocarcinoma: impact of EGFR mutation status on incidence and survival Radiol Oncol 2014 48 173 83 10.2478/raon-2014-0016407803624991207Open DOISearch in Google Scholar

36Shinde A, Akhavan D, Sedrak M, Glaser S, Amini A. Shifting paradigms: whole brain radiation therapy versus stereotactic radiosurgery for brain metastases. CNS Oncol 2019; 8: CNS27. doi: 10.2217/cns-2018-0016 Shinde A Akhavan D Sedrak M Glaser S Amini A Shifting paradigms: whole brain radiation therapy versus stereotactic radiosurgery for brain metastases CNS Oncol 2019 8 CNS27 10.2217/cns-2018-0016649901530701987Open DOISearch in Google Scholar

37Roeper J, Kurz S, Grohé C, Griesinger F. Optimizing therapy sequence to prevent patient attrition in EGFR mutation-positive advanced or metastatic NSCLC. Future Oncol 2021; 17: 471-86. doi: 10.2217/fon-2020-0854 Roeper J Kurz S Grohé C Griesinger F Optimizing therapy sequence to prevent patient attrition in EGFR mutation-positive advanced or metastatic NSCLC Future Oncol 2021 17 471 86 10.2217/fon-2020-085433094641Open DOISearch in Google Scholar

38Nadler E, Pavilack M, Espirito JL, Clark J, Fernandes A. Observational study of treatment patterns in patients with epidermal growth factor receptor (EGFR) mutation-positive non-small cell lung cancer after first-line EGFR-tyrosine kinase inhibitors. Adv Ther 2020; 37: 946-54. doi: 10.1007/ s12325-020-01221-4 Nadler E Pavilack M Espirito JL Clark J Fernandes A Observational study of treatment patterns in patients with epidermal growth factor receptor (EGFR) mutation-positive non-small cell lung cancer after first-line EGFR-tyrosine kinase inhibitors Adv Ther 2020 37 946 54 10.1007/s12325-020-01221-431955357Open DOISearch in Google Scholar

39Wang F, Li C, Wu Q, Lu H. EGFR exon 20 insertion mutations in non-small cell lung cancer. Transl Cancer Res 2020; 9: 2982-91. doi: 10.21037/ tcr.2020.03.10 Wang F Li C Wu Q Lu H EGFR exon 20 insertion mutations in non-small cell lung cancer Transl Cancer Res 2020 9 2982 91 10.21037/tcr.2020.03.10879901235117654Open DOISearch in Google Scholar

40Remon J, Hendriks LEL, Cardona AF, Besse B. EGFR exon 20 insertions in advanced non-small cell lung cancer: a new history begins. Cancer Treat Rev 2020; 90: 102105. doi: 10.1016/j.ctrv.2020.102105 Remon J Hendriks LEL Cardona AF Besse B EGFR exon 20 insertions in advanced non-small cell lung cancer: a new history begins Cancer Treat Rev 2020 90 102105 10.1016/j.ctrv.2020.10210532979839Open DOISearch in Google Scholar

41Dent RAG, Cole P. In vitro maturation of monocytes in squamous carcinoma of the lung. Br J Cancer 1981; 43: 486-95. doi: 10.1038/bjc.1981.71 Dent RAG Cole P In vitro maturation of monocytes in squamous carcinoma of the lung Br J Cancer 1981 43 486 95 10.1038/bjc.1981.7120106367236490Open DOISearch in Google Scholar

42Sterne JA, Hernan MA, Reeves BC, Savovic J, Berkman ND, Viswanathan M, et al. ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions. BMJ 2016; 355: i4919. doi: 10.1136/bmj.i4919 Sterne JA Hernan MA Reeves BC Savovic J Berkman ND Viswanathan M et al ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions BMJ 2016 355 i4919 10.1136/bmj.i4919506205427733354Open DOISearch in Google Scholar

43Chapman S, Nakielny R. A guide to radiological procedures. London: Bailliere Tindall; 1986. Chapman S Nakielny R A guide to radiological procedures London Bailliere Tindall 1986Search in Google Scholar

44Evans R, Alexander P. Mechanisms of extracellular killing of nucleated mammalian cells by macrophages. In: Nelson DS, editor. Immunobiology of macrophage. New York: Academic Press; 1976. p. 45-74. Evans R Alexander P Mechanisms of extracellular killing of nucleated mammalian cells by macrophages In Nelson DS editor Immunobiology of macrophage New York Academic Press; 1976 p 45–7410.1016/B978-0-12-514550-3.50027-XSearch in Google Scholar